Title

Evaluating outcomes of renal angioembolization: A retrospective study

Authors

Rana Pratap Singh¹, Prashant Kumar² & Prabin Kumar Shrivastava²*

Affiliation

¹Department of Urology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India; ²Department of Cardiology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India; *Corresponding author

Email

Rana Pratap Singh - E-mail: ranapratapsingh02@gmail.com
Prashant Kumar - E-mail: prashant87897@gmail.com
Prabin Kumar Shrivastava - E-mail: prabinrimscardiology@gmail.com

Article Type

Research Article

Date

Received November 15, 2025; Revised December 15, 2025; Accepted December 15, 2025, Published December 15, 2025

Abstract

Acute renal hemorrhage requires rapid, nephron-sparing management and renal angioembolization (RAE) has emerged as a minimally invasive alternative to surgery, though outcome data from varied clinical settings remain limited. Therefore, it is of interest to evaluate 79 patients who underwent RAE between January 2018 and January 2023, assessing technical and clinical success, complications and renal function changes. High-grade renal trauma (45.6%) and iatrogenic injury (29.1%) were the leading indications. RAE achieved a technical success rate of 98.7% and clinical success in 93.7% of patients, with post-embolization syndrome being the most common complication (26.6%) and major complications rare (1.3%). Thus, we show that RAE is a highly effective, safe and nephron-sparing first-line treatment for acute renal hemorrhage.

Keywords

Renal Angioembolization (RAE), renal trauma, iatrogenic injury, interventional cardiology and urology, minimally invasive surgery, angiomyolipoma, renal artery embolization

Citation

Singh et al. Bioinformation 21(12): 4869-4872 (2025)

Edited by

Hiroj Bagde

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.